| Literature DB >> 26347202 |
Zhongfei Xu1, Enjiao Zhang1, Weiyi Duan1, Changfu Sun1, Shuang Bai1, Xuexin Tan1.
Abstract
BACKGROUND: MicroRNAs are a class of new noncoding RNA that play important roles in the pathogenesis of tumor. Rs3746444 in miR-499 is suggested to be associated with cancer susceptibility. In the present study, we assess the association between miR-499 rs3746444 polymorphism and cancer susceptibility through a meta-analysis.Entities:
Keywords: microRNA; risk factor; single-nucleotide polymorphism; tumor
Year: 2015 PMID: 26347202 PMCID: PMC4550183 DOI: 10.2147/OTT.S88224
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Flowchart of the study selection process.
Characteristics of all the studies in the meta-analysis
| Authors, year | Country | Ethnicity | Cancer type | Genotyping method | Study design | Number(cases/controls) | Cases
| Controls
| HWE ( | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | AG | GG | Frequency of G allele | AA | AG | GG | Frequency of G allele | ||||||||
| Hu et al | People’s Republic of China | Asian | BC | PCR-RFLP | PB | 1,009/1,093 | 707 | 258 | 44 | 0.171 | 816 | 248 | 29 | 0.140 | 0.06 |
| Tian et al | People’s Republic of China | Asian | LC | PCR-RFLP | PB | 1,058/1,035 | 781 | 253 | 24 | 0.142 | 755 | 254 | 26 | 0.148 | 0.40 |
| Srivastava et al | India | Caucasian | GBC | PCR-RFLP | PB | 230/230 | 112 | 97 | 21 | 0.302 | 121 | 94 | 15 | 0.270 | 0.57 |
| Liu et al | USA | Caucasian | SCCHN | PCR-RFLP | HB | 1,109/1,130 | 745 | 309 | 55 | 0.189 | 710 | 366 | 54 | 0.210 | 0.44 |
| Okubo et al | Japan | Asian | GC | PCR-RFLP | HB | 552/697 | 364 | 151 | 37 | 0.204 | 466 | 198 | 33 | 0.189 | 0.05 |
| Catucci et al | Italy, Germany | Caucasian | BC | TaqMan PCR | PB | 1,579/2,167 | 950 | 545 | 84 | 0.226 | 1,305 | 742 | 120 | 0.227 | 0.28 |
| Zhou et al | People’s Republic of China | Asian | CSCC | PCR-RFLP | PB | 226/309 | 134 | 84 | 8 | 0.221 | 223 | 71 | 15 | 0.163 | 0.005 |
| George et al | India | Caucasian | PC | PCR-RFLP | PB | 159/230 | 48 | 98 | 13 | 0.390 | 104 | 92 | 34 | 0.348 | 0.07 |
| Mittal et al | India | Caucasian | BC | PCR-RFLP | PB | 212/250 | 95 | 92 | 25 | 0.335 | 121 | 94 | 35 | 0.328 | 0.02 |
| Akkiz et al | Turkey | Caucasian | HCC | PCR-RFLP | PB | 222/222 | 45 | 87 | 90 | 0.601 | 47 | 93 | 82 | 0.579 | 0.04 |
| Zhou et al | People’s Republic of China | Asian | HCC | PCR-RFLP | PB | 186/483 | 141 | 41 | 4 | 0.132 | 371 | 100 | 12 | 0.128 | 0.1 |
| Xiang et al | People’s Republic of China | Asian | HCC | PCR-RFLP | HB | 100/100 | 36 | 40 | 24 | 0.440 | 54 | 36 | 10 | 0.280 | 0.28 |
| Kim et al | Korea | Asian | HCC | PCR-RFLP | PB | 159/201 | 109 | 47 | 3 | 0.167 | 120 | 74 | 7 | 0.219 | 0.28 |
| Wei et al 2013 | People’s Republic of China | Asian | ESCC | PCR | HB | 358/376 | 291 | 60 | 7 | 0.103 | 289 | 76 | 11 | 0.130 | 0.110 |
| Vinci et al | Italy | Caucasian | CRC | TaqMan PCR | HB | 160/178 | 93 | 32 | 35 | 0.319 | 105 | 56 | 17 | 0.253 | 0.083 |
| Hu et al 2014 | People’s Republic of China | Asian | CRC | PCR-RFLP | HB | 276/373 | 157 | 49 | 5 | 0.140 | 282 | 81 | 10 | 0.135 | 0.376 |
| Hasani et al | Iran | Asian | ALL | TARMS-PCR | HB | 75/115 | 35 | 28 | 12 | 0.347 | 61 | 42 | 12 | 0.287 | 0.514 |
| Omrani et al | Iran | Asian | BC | PCR | HB | 236/203 | 131 | 44 | 61 | 0.352 | 130 | 48 | 25 | 0.241 | 0.000 |
Note:
The distribution of genotypes in the controls was not in HWE when its P-value was <0.05.
Abbreviations: ALL, acute lymphocytic leukemia; BC, breast cancer; CRC, colorectal cancer; CSCC, cervical squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; GBC, gallbladder cancer; GC, gastric cancer; HB, hospital-based; HCC, hepatocellular carcinoma; HWE, Hardy–Weinberg equilibrium; LC, lung cancer; PB, population-based; PC, prostate cancer; PCR, polymerase chain reaction; PCR-RFLP, PCR–restriction fragment length polymorphism; SCCHN, squamous cell carcinoma of head and neck; TARMS-PCR, tetra-primer amplification refractory mutation system polymerase chain reaction.
Association between miR-499 (rs3746444) and cancer risk
| Number of datasets | Fixed-effects, OR (95% CI) | Random-effects, OR (95% CI) | |||
|---|---|---|---|---|---|
| AG versus AA | 18 | 1.03 (0.96–1.10) | 1.06 (0.94–1.21) | 0.000 | 62.7 |
| GG versus AA | 18 | 1.21 (1.06–1.39) | 1.24 (1.01–1.52) | 0.014 | 47.1 |
| GG + AG versus AA | 18 | 1.05 (0.99–1.12) | 1.11 (0.99–1.24) | 0.000 | 61.1 |
| GG versus AG + AA | 18 | 1.18 (1.04–1.35) | 1.19 (0.97–1.48) | 0.002 | 55.5 |
| G versus A | 18 | 1.07 (1.01–1.13) | 1.11 (1.01–1.23) | 0.000 | 65.6 |
Notes: The between-study heterogeneity was assessed by P-values of the Cochran’s Q test (Phet) and I2 (a significance level of P<0.05 or I2≥50%). The significance of association was evaluated by odds ratios (ORs) and their 95% confidence intervals (CIs) in a fixed-effects or random-effects model.
Figure 2Meta-analysis of the association between miR-499 polymorphism and cancer risk under the homogeneity model (GG versus AA).
Note: Weights are from random-effects analysis.
Abbreviations: CI, confidence interval; OR, odds ratio.
Figure 3Meta-analysis of the association between miR-499 polymorphism and cancer risk under the allelic model (G versus A).
Note: Weights are from random-effects analysis.
Abbreviations: CI, confidence interval; OR, odds ratio.
Pooled ORs and 95% CIs for miR-499 polymorphism from stratified meta-analysis
| Subgroup | Genotype | Number of studies | Test of association
| Test of heterogeneity
| |||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | Model | Phet | |||||
| Asian | AG versus AA | 13 | 1.14 (0.97–1.35) | 0.113 | R | 0.001 | 63.3 |
| GG versus AA | 13 | 1.32 (1.09–1.59) | 0.004 | F | 0.024 | 48.8 | |
| GG + AG versus AA | 13 | 1.17 (1.01–1.37) | 0.044 | R | 0.001 | 62.9 | |
| GG versus AG + AA | 13 | 1.14 (0.84–1.54) | 0.418 | R | 0.004 | 58.4 | |
| G versus A | 13 | 1.14 (1.00–1.31) | 0.050 | R | 0.000 | 66.5 | |
| Caucasian | AG versus AA | 5 | 0.93 (0.84–1.03) | 0.159 | F | 0.161 | 39.0 |
| GG versus AA | 5 | 1.11 (0.92–1.35) | 0.277 | F | 0.125 | 44.5 | |
| GG + AG versus AA | 5 | 0.96 (0.87–1.06) | 0.388 | F | 0.321 | 14.6 | |
| GG versus AG + AA | 5 | 1.24 (0.92–1.66) | 0.156 | R | 0.059 | 56.0 | |
| G versus A | 5 | 1.04 (0.91–1.18) | 0.599 | R | 0.081 | 51.8 | |
| HCC | AG versus AA | 4 | 0.99 (0.78–1.26) | 0.963 | F | 0.156 | 42.5 |
| GG versus AA | 4 | 1.27 (0.60–2.69) | 0.540 | R | 0.040 | 63.8 | |
| GG + AG versus AA | 4 | 1.09 (0.73–1.64) | 0.674 | R | 0.024 | 68.2 | |
| GG versus AG + AA | 4 | 1.26 (0.70–2.27) | 0.447 | R | 0.107 | 50.8 | |
| G versus A | 4 | 1.12 (0.78–1.62) | 0.547 | R | 0.004 | 77.5 | |
| BC | AG versus AA | 4 | 1.07 (0.96–1.19) | 0.210 | F | 0.395 | 0.0 |
| GG versus AA | 4 | 1.37 (0.86–2.17) | 0.181 | R | 0.070 | 75.6 | |
| GG + AG versus AA | 4 | 1.11 (1.00–1.22) | 0.051 | F | 0.133 | 46.4 | |
| GG versus AG + AA | 4 | 1.33 (0.83–2.14) | 0.242 | R | 0.003 | 78.3 | |
| G versus A | 4 | 1.20 (0.97–1.49) | 0.100 | R | 0.002 | 79.6 | |
| CC | AG versus AA | 2 | 0.86 (0.52–1.43) | 0.558 | R | 0.119 | 58.8 |
| GG versus AA | 2 | 1.61 (0.65–3.99) | 0.306 | R | 0.141 | 53.8 | |
| GG + AG versus AA | 2 | 1.05 (0.78–1.41) | 0.729 | F | 0.924 | 0.0 | |
| GG versus AG + AA | 2 | 1.68 (0.58–4.86) | 0.340 | R | 0.085 | 66.3 | |
| G versus A | 2 | 1.20 (0.95–1.53) | 0.129 | F | 0.243 | 26.6 | |
Notes: The significance of association was evaluated by ORs and their 95% CIs. The between-study heterogeneity was assessed by P-values of the Cochran’s Q test (Phet) and I2 (a significance level of P<0.05 or I2≥50%).
Abbreviations: BC, breast cancer; CC, colorectal cancer; CI, confidence interval; F, fixed-effects model; HCC, hepatocellular carcinoma; OR, odds ratio; R, random-effects model.